CA2928656C - Nicotinamide riboside compositions for topical use in treating skin conditions - Google Patents
Nicotinamide riboside compositions for topical use in treating skin conditions Download PDFInfo
- Publication number
- CA2928656C CA2928656C CA2928656A CA2928656A CA2928656C CA 2928656 C CA2928656 C CA 2928656C CA 2928656 A CA2928656 A CA 2928656A CA 2928656 A CA2928656 A CA 2928656A CA 2928656 C CA2928656 C CA 2928656C
- Authority
- CA
- Canada
- Prior art keywords
- nicotinamide riboside
- composition
- salt
- skin
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000020956 nicotinamide riboside Nutrition 0.000 title claims abstract description 142
- 239000011618 nicotinamide riboside Substances 0.000 title claims abstract description 142
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000000699 topical effect Effects 0.000 title description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 57
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 210000003491 skin Anatomy 0.000 claims description 66
- -1 nicotinamide riboside compound Chemical class 0.000 claims description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 230000005778 DNA damage Effects 0.000 claims description 17
- 231100000277 DNA damage Toxicity 0.000 claims description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 16
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 16
- 210000004927 skin cell Anatomy 0.000 claims description 14
- 230000004792 oxidative damage Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 8
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 8
- 229910002651 NO3 Inorganic materials 0.000 claims description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 8
- 229940072107 ascorbate Drugs 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 150000003841 chloride salts Chemical class 0.000 claims description 8
- 229940044170 formate Drugs 0.000 claims description 8
- 229940050410 gluconate Drugs 0.000 claims description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 229940001447 lactate Drugs 0.000 claims description 8
- 229940102396 methyl bromide Drugs 0.000 claims description 8
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 8
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 7
- 230000030833 cell death Effects 0.000 claims description 7
- 239000001177 diphosphate Substances 0.000 claims description 7
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 7
- 235000011180 diphosphates Nutrition 0.000 claims description 7
- 238000011200 topical administration Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000004899 motility Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims 4
- 239000013635 pyrimidine dimer Substances 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 20
- 230000032683 aging Effects 0.000 abstract description 17
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 230000004083 survival effect Effects 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 230000037041 intracellular level Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 76
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 28
- 239000012091 fetal bovine serum Substances 0.000 description 28
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 230000004888 barrier function Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 230000005855 radiation Effects 0.000 description 11
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 230000033616 DNA repair Effects 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 8
- 150000003436 stilbenoids Chemical class 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 7
- 206010020649 Hyperkeratosis Diseases 0.000 description 6
- 208000001126 Keratosis Diseases 0.000 description 6
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 6
- 108091093078 Pyrimidine dimer Proteins 0.000 description 6
- 108010041191 Sirtuin 1 Proteins 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000001738 genotoxic effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000008832 photodamage Effects 0.000 description 6
- 230000004224 protection Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 230000036572 transepidermal water loss Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000011990 Sirtuin Human genes 0.000 description 5
- 108050002485 Sirtuin Proteins 0.000 description 5
- 206010040799 Skin atrophy Diseases 0.000 description 5
- 206010050637 Skin tightness Diseases 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000036569 collagen breakdown Effects 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 231100000025 genetic toxicology Toxicity 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 230000037393 skin firmness Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 4
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000004700 rosacea Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 208000035484 Cellulite Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 206010049752 Peau d'orange Diseases 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 229960003328 benzoyl peroxide Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000036232 cellulite Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002113 chemopreventative effect Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000037365 barrier function of the epidermis Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000020827 calorie restriction Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000001767 chemoprotection Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MAKBMGXNXXXBFE-TURQNECASA-N 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MAKBMGXNXXXBFE-TURQNECASA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 206010016845 Foetal alcohol syndrome Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 1
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 108091026813 Poly(ADPribose) Proteins 0.000 description 1
- 101710173609 Protein ADP-ribosyltransferase Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000009222 cellular stress response pathway Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 231100000446 genotoxin Toxicity 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009221 stress response pathway Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361897713P | 2013-10-30 | 2013-10-30 | |
| US61/897,713 | 2013-10-30 | ||
| PCT/US2014/063260 WO2015066382A1 (en) | 2013-10-30 | 2014-10-30 | Nicotinamide riboside compositions for topical use in treating skin conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2928656A1 CA2928656A1 (en) | 2015-05-07 |
| CA2928656C true CA2928656C (en) | 2020-07-28 |
Family
ID=53005146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2928656A Active CA2928656C (en) | 2013-10-30 | 2014-10-30 | Nicotinamide riboside compositions for topical use in treating skin conditions |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10688118B2 (enExample) |
| EP (1) | EP3063163B1 (enExample) |
| JP (1) | JP6509844B2 (enExample) |
| KR (3) | KR20160067195A (enExample) |
| CN (2) | CN105873937A (enExample) |
| AU (1) | AU2014342185B2 (enExample) |
| CA (1) | CA2928656C (enExample) |
| ES (1) | ES2925879T3 (enExample) |
| MX (2) | MX385305B (enExample) |
| NZ (1) | NZ719328A (enExample) |
| WO (1) | WO2015066382A1 (enExample) |
| ZA (1) | ZA201603314B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016149764A (ru) * | 2014-06-02 | 2018-07-17 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Получение и применение кристаллического бета-d-никотинамида рибозида |
| EP3152220A1 (en) | 2014-06-06 | 2017-04-12 | Glaxosmithkline Intellectual Property (No. 2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
| ES2908332T3 (es) | 2014-07-24 | 2022-04-28 | Grace W R & Co | Forma cristalina de cloruro de ribosilnicotinamida |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| KR102426320B1 (ko) * | 2015-03-16 | 2022-07-29 | 크로마덱스 아이엔씨. | 니코틴산 리보사이드 또는 니코틴아미드 리보사이드 조성물, 이의 환원 유도체, 및 이의 용도 |
| WO2016178945A1 (en) | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
| US20160317418A1 (en) | 2015-05-01 | 2016-11-03 | The Procter & Gamble Company | Method of improving the appearance of skin and compositions therefor |
| WO2016178949A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
| CN107849083A (zh) | 2015-06-10 | 2018-03-27 | 益力舒健康公司 | 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法 |
| WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| WO2017004101A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Skin care compositions comprising particles with nicotinamide riboside and methods of using the same |
| WO2017004100A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Encapsulated particles comprising nicotinamide riboside |
| CN115414273B (zh) | 2016-01-11 | 2024-01-30 | 宝洁公司 | 处理皮肤状况的方法以及用于其的组合物 |
| CA3017254C (en) | 2016-03-16 | 2023-08-22 | ChromaDex Inc. | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| KR20190008246A (ko) * | 2016-04-20 | 2019-01-23 | 크로마덱스 아이엔씨. | Nad+ 증가용 전구체로서 니코틴산 리보사이드 또는 니코틴아미드 리보사이트 유도체 및 이의 환원된 유도체의 용도 |
| MX2019002211A (es) * | 2016-08-22 | 2019-10-30 | Elysium Health Inc | Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. |
| CN120383644A (zh) | 2016-11-11 | 2025-07-29 | 英国贝尔法斯特女王大学 | 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成 |
| JP7136795B2 (ja) | 2016-11-29 | 2022-09-13 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用 |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| CA3046037A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
| WO2018114749A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with cystine |
| EA038885B1 (ru) | 2016-12-21 | 2021-11-02 | ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. | Осветляющая кожу добавка для местного применения и композиция с аминокислотами и никотинамидными соединениями |
| CN110121331B (zh) | 2016-12-21 | 2022-09-16 | 联合利华知识产权控股有限公司 | 含有难溶性化合物的个人护理组合物 |
| RU2651047C1 (ru) * | 2017-05-04 | 2018-04-18 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Лекарственная композиция цитопротекторного действия и способ ее получения |
| EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| WO2018237218A1 (en) | 2017-06-23 | 2018-12-27 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| WO2019023471A1 (en) * | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING |
| EP3682746A4 (en) * | 2017-09-14 | 2021-03-10 | Megumi Tanaka | AGING PROTECTION AGENTS AND AGING PROTECTION PROCEDURES |
| GB201716391D0 (en) * | 2017-10-06 | 2017-11-22 | Xobaderm Ltd | Kit for delivery of an active compound into a biological barrier |
| JP2021506898A (ja) | 2017-12-22 | 2021-02-22 | エリシウム ヘルス，インコーポレーテッド | ニコチンアミドリボシドクロリドの結晶形態 |
| KR20210011964A (ko) | 2018-07-03 | 2021-02-02 | 더 프록터 앤드 갬블 캄파니 | 피부 병태를 치료하는 방법 |
| JP6887025B2 (ja) * | 2018-08-17 | 2021-06-16 | 邦泰生物工程（深▲セン▼）有限公司 | 安定型ニコチンアミドリボシド組成物及びその調製方法 |
| KR102060374B1 (ko) * | 2018-12-14 | 2019-12-30 | 주식회사 휴메딕스 | 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN119684381A (zh) | 2019-07-19 | 2025-03-25 | 生物合成股份公司 | 烟酰胺呋喃核糖苷盐的结晶形式以及包含其的营养补充剂和药物组合物 |
| CN110638827A (zh) * | 2019-10-17 | 2020-01-03 | 泓博元生命科技（深圳）有限公司 | Nadh及其盐在制备皮肤色素抑制剂中的应用 |
| KR102315139B1 (ko) | 2019-12-17 | 2021-10-20 | 주식회사 휴메딕스 | 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체 |
| CN111166760A (zh) * | 2019-12-17 | 2020-05-19 | 浙江安赛新材料科技有限公司 | β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用 |
| CN111184732B (zh) * | 2020-03-04 | 2023-09-08 | 武汉华纳联合药业有限公司 | 一种复合组合物制剂及其制备方法和皮肤炎症中的应用 |
| CN111454311B (zh) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| US20230210746A1 (en) * | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| FR3110410A1 (fr) * | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
| JP7590462B2 (ja) | 2020-06-01 | 2024-11-26 | ザ プロクター アンド ギャンブル カンパニー | ビタミンｂ３化合物の皮膚への浸透を改善する方法 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| CN111632049A (zh) * | 2020-06-09 | 2020-09-08 | 西北农林科技大学 | 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方 |
| US20230263817A1 (en) * | 2020-08-28 | 2023-08-24 | University Of Washington | High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation |
| US20240059727A1 (en) * | 2021-01-19 | 2024-02-22 | Biosynth Ag | Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt |
| US20220354879A1 (en) * | 2021-05-04 | 2022-11-10 | Sovida Solutions Ltd. | Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof |
| CN114129509B (zh) * | 2021-12-03 | 2023-12-01 | 药酚享科技(北京)有限公司 | 一种保湿性nmn亲水凝胶剂及其制备方法 |
| CN114933621A (zh) * | 2022-04-13 | 2022-08-23 | 深圳市迪克曼生物科技有限公司 | 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途 |
| KR102784901B1 (ko) * | 2022-06-23 | 2025-03-21 | 제너럴바이오(주) | Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067889A2 (en) * | 2001-02-22 | 2002-09-06 | Unilever Plc | Skin composition for reducing skin oils and grease |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| AU2005211773B2 (en) | 2004-02-10 | 2009-06-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| DK1755391T3 (en) | 2004-06-04 | 2016-02-08 | Univ Washington | METHODS AND COMPOSITIONS FOR THE TREATMENT OF neuropathies |
| CA2610854A1 (en) | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
| WO2007061798A2 (en) | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| ES2439582T3 (es) * | 2007-03-12 | 2014-01-23 | Dsm Ip Assets B.V. | Composiciones cosméticas |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| MX2012007873A (es) * | 2010-01-06 | 2012-07-25 | Yakult Honsha Kk | Promotor de reparacion del daño de acido desoxirribonucleico para aplicacion oral e inhibidor de la actividad de elastasa para apalicacion oral. |
-
2014
- 2014-10-30 CN CN201480071722.4A patent/CN105873937A/zh active Pending
- 2014-10-30 JP JP2016526337A patent/JP6509844B2/ja active Active
- 2014-10-30 KR KR1020167014302A patent/KR20160067195A/ko not_active Ceased
- 2014-10-30 NZ NZ719328A patent/NZ719328A/en unknown
- 2014-10-30 AU AU2014342185A patent/AU2014342185B2/en active Active
- 2014-10-30 KR KR1020227022241A patent/KR20220098049A/ko not_active Ceased
- 2014-10-30 MX MX2016005574A patent/MX385305B/es unknown
- 2014-10-30 CA CA2928656A patent/CA2928656C/en active Active
- 2014-10-30 KR KR1020217026414A patent/KR20210107895A/ko not_active Ceased
- 2014-10-30 ES ES14857903T patent/ES2925879T3/es active Active
- 2014-10-30 WO PCT/US2014/063260 patent/WO2015066382A1/en not_active Ceased
- 2014-10-30 MX MX2021009652A patent/MX394291B/es unknown
- 2014-10-30 CN CN201910027571.7A patent/CN109985056A/zh active Pending
- 2014-10-30 EP EP14857903.0A patent/EP3063163B1/en active Active
- 2014-10-30 US US15/033,285 patent/US10688118B2/en active Active
-
2016
- 2016-05-16 ZA ZA2016/03314A patent/ZA201603314B/en unknown
-
2020
- 2020-06-03 US US16/891,824 patent/US11033568B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021009652A (es) | 2022-07-26 |
| ZA201603314B (en) | 2017-09-27 |
| WO2015066382A1 (en) | 2015-05-07 |
| KR20160067195A (ko) | 2016-06-13 |
| US11033568B2 (en) | 2021-06-15 |
| US10688118B2 (en) | 2020-06-23 |
| AU2014342185B2 (en) | 2019-01-03 |
| KR20220098049A (ko) | 2022-07-08 |
| JP6509844B2 (ja) | 2019-05-08 |
| ES2925879T3 (es) | 2022-10-20 |
| CA2928656A1 (en) | 2015-05-07 |
| MX2016005574A (es) | 2016-12-09 |
| NZ719328A (en) | 2022-04-29 |
| CN105873937A (zh) | 2016-08-17 |
| EP3063163A4 (en) | 2017-05-10 |
| MX385305B (es) | 2025-03-18 |
| US20200289536A1 (en) | 2020-09-17 |
| EP3063163A1 (en) | 2016-09-07 |
| CN109985056A (zh) | 2019-07-09 |
| JP2016538271A (ja) | 2016-12-08 |
| EP3063163B1 (en) | 2022-08-10 |
| MX394291B (es) | 2025-03-24 |
| KR20210107895A (ko) | 2021-09-01 |
| US20160250241A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11033568B2 (en) | Nicotinamide riboside compositions for topical use in treating skin conditions | |
| AU2014342185A1 (en) | Nicotinamide riboside compositions for topical use in treating skin conditions | |
| ES2234537T3 (es) | Composicion cosmetica que comprende al menos un hidroxiestilbeno y acido ascorbico. | |
| AU2016233247B2 (en) | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof | |
| ES2316647T3 (es) | Composiciones para el tratamiento anti-irritante de la rosacea. | |
| ES2743446T3 (es) | Dispositivos para proporcionar el cuidado de la piel mediante el uso de fototerapia | |
| JP2012502020A (ja) | ポリヒドロキシルテート（ｐｏｌｙｈｙｄｒｏｘｙｌｔａｔｅ）脂肪アルコールおよび誘導体を含む化粧品組成物およびその使用 | |
| AU2019204136A1 (en) | Compositions and methods for treating skin conditions using light and glucosamine hydrochloride | |
| KR101186130B1 (ko) | 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물 | |
| Singh et al. | Niosomes-a novel tool for anti-ageing cosmeceuticals | |
| ES2794901T3 (es) | Composiciones y métodos para tratar afecciones de la piel con luz y ácidos policarboxílicos | |
| JP7583777B2 (ja) | 色素沈着過剰障害の処置方法 | |
| CN113038920A (zh) | 用于治疗美学皮肤病症的铁螯合化合物 | |
| KR20080080253A (ko) | 펩타이드 유도체를 함유하는 화장료 조성물 | |
| HK40011054A (en) | Nicotinamide nucleoside composition for topical use in the treatment of dermatosis | |
| ES2396572T3 (es) | Utilización de una composición que comprende una asociación de hidroquinona de acetonida, de fluocinolona, y de tretinoina, destinada al tratamiento de los signos cutáneos de fotoenvejecimiento | |
| BR112018011580B1 (pt) | Compostos de éster, compostos de amida, composição e uso de pelo menos um composto | |
| KR101326026B1 (ko) | 펩타이드 유도체를 함유하는 화장료 조성물 | |
| CA3084891A1 (en) | Compositions and methods for treating skin conditions using infrared light and resorcinols | |
| RU2793250C2 (ru) | Композиция и способы лечения патологических состояний кожи; использование света и гидрохлорида глюкозамина | |
| Thappa et al. | Newer Agents for Topical Treatment | |
| MX2007006059A (es) | Composicion de crema desmanchadora de piel. | |
| BR102016022420A2 (pt) | Composição tópica, uso cosmético da composição e composição tópica e dermatológica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191030 |